AURA Form 4 reports sale transactions

Hopkins Janet Jill reported open-market sale transactions in a Form 4 filing for AURA.

Rhea-AI Filing Summary

Hopkins Janet Jill reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 20,401 shares at a weighted average price of $5.06 per share. Following the reported transactions, holdings were 232,284 shares.

Insider Trade Summary

Net Seller: 20,401 shares

Net Sell 1 txn

Insider Hopkins Janet Jill

Role Chief Medical Officer

Sold 20,401 shs ($103K)

Type	Security	Shares	Price	Value
Sale	Common Stock	20,401	$5.06	$103K

Holdings After Transaction: Common Stock — 232,284 shares (Direct)

Footnotes (2)

1. F1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aura Biosciences (AURA) disclose about Janet Hopkins in this Form 4?

Aura Biosciences disclosed that Chief Medical Officer Janet Jill Hopkins sold 20,401 shares of common stock. The filing states these automatic sales covered tax withholding obligations from vesting restricted stock units and were not discretionary trades initiated for portfolio or investment reasons.

How many Aura Biosciences (AURA) shares did Janet Hopkins sell and at what price?

Janet Hopkins sold 20,401 shares of Aura Biosciences common stock at a weighted average price of $5.06 per share. A footnote explains the trades occurred in multiple transactions between $5.04 and $5.31 per share, all recorded as one aggregated sale.

Why did Aura Biosciences CMO Janet Hopkins sell shares according to the Form 4?

The Form 4 explains that the shares were sold to cover tax withholding obligations related to vesting restricted stock units. These tax-related sales were automatic under the company’s procedures and, according to the filing, were not executed at Hopkins’ personal trading discretion.

How many Aura Biosciences (AURA) shares does Janet Hopkins own after the reported sale?

Following the tax-related sale, Janet Hopkins beneficially owns 232,284 shares of Aura Biosciences common stock. This post-transaction holding reflects her remaining direct ownership after selling 20,401 shares to satisfy withholding taxes tied to the vesting of restricted stock units.

What does the price range footnote in Janet Hopkins’ Aura Biosciences Form 4 mean?

The filing notes the $5.06 price is a weighted average of multiple trades executed between $5.04 and $5.31 per share. Hopkins undertakes to provide detailed breakdowns of individual trade prices and volumes upon request to the company, shareholders, or the SEC staff.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 07:47 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopkins Janet Jill

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		S(1)		20,401	D	$5.06(2)	232,284	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Conor Kilroy, as Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.